This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Oncology diagnostics

KEYTRUDA® (pembrolizumab) Prescribing Information

PINPOINT Informing the right treatment for the right patient PINPOINT Informing the right treatment for the right patient

Biomarkers are changing the healthcare field towards greater personalised medicine. With these changes come new challenges for healthcare professionals to stay up to date and trained.

PinPoint is MSD’s Oncology Diagnostics hub with a goal to provide sought-after practical support for pathologists to help navigate the complex and changing testing landscape.

MSD aims to be a leading pioneer and partner in precision medicine, increasing clinical benefit and economic value through improved patient selection.

Performing PD-L1 testing in certain tumour types can help select patients who could benefit from immunotherapy.

Please log in to gain access

For optimal functionality, please access the image bank and self-scoring pages via desktop devices. Some functionality may be lost on mobile devices.

Image bank

View

Here you can review images of PD-L1 stained samples of different tumours, with available consensus score, accompanied by images of corresponding H&E (Haematoxylin and Eosin) stains.

Self-scoring

View

For help in practicing TPS and CPS scoring of PD-L1 expression in different indications, this section allows you to review images of PD-L1 stained slides (with corresponding H&E slides) and check your knowledge and PD-L1 expression estimate against the consensus score for each case.

Image bank

Here you can review images of PD-L1 stained samples of different tumours, with available consensus score, accompanied by images of corresponding H&E (Haematoxylin and Eosin) stains.

View

Self-scoring

For help in practicing TPS and CPS scoring of PD-L1 expression in different indications, this section allows you to review images of PD-L1 stained slides (with corresponding H&E slides) and check your knowledge and PD-L1 expression estimate against the consensus score for each case.

View

Tumour Positive Score vs. Combined Positive Score

Length: 04:47

Animated video giving an overview of PD-L1 testing and the two algorithms used for PD-L1 scoring in assessment of eligible patients for KEYTRUDA® (pembrolizumab) in certain indications. Please see the Summary of Product Characteristics and the references at the end of the video for further information.

Supporting documentation

KEYTRUDA® (pembrolizumab)
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-PDO-01086 | Date of Preparation: September 2020

Oncology diagnostics

KEYTRUDA® (pembrolizumab) Prescribing Information

PINPOINT Informing the right treatment for the right patient PINPOINT Informing the right treatment for the right patient

Biomarkers are changing the healthcare field towards greater personalised medicine. With these changes come new challenges for healthcare professionals to stay up to date and trained.

PinPoint is MSD’s Oncology Diagnostics hub with a goal to provide sought-after practical support for pathologists to help navigate the complex and changing testing landscape.

MSD aims to be a leading pioneer and partner in precision medicine, increasing clinical benefit and economic value through improved patient selection.

Performing PD-L1 testing in certain tumour types can help select patients who could benefit from immunotherapy.

Image bank

View

Here you can review images of PD-L1 stained samples of different tumours, with available consensus score, accompanied by images of corresponding H&E (Haematoxylin and Eosin) stains.

Self-scoring

View

For help in practicing TPS and CPS scoring of PD-L1 expression in different indications, this section allows you to review images of PD-L1 stained slides (with corresponding H&E slides) and check your knowledge and PD-L1 expression estimate against the consensus score for each case.

Image bank

Here you can review images of PD-L1 stained samples of different tumours, with available consensus score, accompanied by images of corresponding H&E (Haematoxylin and Eosin) stains.

View

Self-scoring

For help in practicing TPS and CPS scoring of PD-L1 expression in different indications, this section allows you to review images of PD-L1 stained slides (with corresponding H&E slides) and check your knowledge and PD-L1 expression estimate against the consensus score for each case.

View

Tumour Positive Score vs. Combined Positive Score

Length: 04:47

Animated video giving an overview of PD-L1 testing and the two algorithms used for PD-L1 scoring in assessment of eligible patients for KEYTRUDA® (pembrolizumab) in certain indications. Please see the Summary of Product Characteristics and the references at the end of the video for further information.

Supporting documentation

KEYTRUDA® (pembrolizumab)
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-PDO-01086 | Date of Preparation: September 2020